Cited 0 time in
Is ageing a problematic hurdle to the efficacy of first-line atezolizumab plus bevacizumab in hepatocellular carcinoma?
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | An, Jihyun | - |
| dc.contributor.author | Shim, Ju H. | - |
| dc.date.accessioned | 2022-12-20T05:51:16Z | - |
| dc.date.available | 2022-12-20T05:51:16Z | - |
| dc.date.created | 2022-11-02 | - |
| dc.date.issued | 2022-11 | - |
| dc.identifier.issn | 1478-3223 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/172916 | - |
| dc.language | 영어 | - |
| dc.language.iso | en | - |
| dc.publisher | WILEY | - |
| dc.title | Is ageing a problematic hurdle to the efficacy of first-line atezolizumab plus bevacizumab in hepatocellular carcinoma? | - |
| dc.type | Article | - |
| dc.contributor.affiliatedAuthor | An, Jihyun | - |
| dc.identifier.doi | 10.1111/liv.15418 | - |
| dc.identifier.scopusid | 2-s2.0-85138605520 | - |
| dc.identifier.wosid | 000859207600002 | - |
| dc.identifier.bibliographicCitation | LIVER INTERNATIONAL, v.42, no.11, pp.2352 - 2353 | - |
| dc.relation.isPartOf | LIVER INTERNATIONAL | - |
| dc.citation.title | LIVER INTERNATIONAL | - |
| dc.citation.volume | 42 | - |
| dc.citation.number | 11 | - |
| dc.citation.startPage | 2352 | - |
| dc.citation.endPage | 2353 | - |
| dc.type.rims | ART | - |
| dc.type.docType | Editorial Material | - |
| dc.description.journalClass | 1 | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
| dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
| dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/liv.15418 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
